Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants.

Cofield SS, Salter A, Tyry T, Crowe C, Cutter GR, Fox RJ, Marrie RA.

Neurol Clin Pract. 2017 Aug;7(4):333-343. doi: 10.1212/CPJ.0000000000000383.

PMID:
29185555
2.

Cerebellar Dysfunction in Multiple Sclerosis.

Wilkins A.

Front Neurol. 2017 Jun 28;8:312. doi: 10.3389/fneur.2017.00312. eCollection 2017. Review.

3.

Cannabis and Multiple Sclerosis-The Way Forward.

Rudroff T, Honce JM.

Front Neurol. 2017 Jun 23;8:299. doi: 10.3389/fneur.2017.00299. eCollection 2017. No abstract available.

4.

Comparative assessment for hyperaccumulatory and phytoremediation capability of three wild weeds.

Girdhar M, Sharma NR, Rehman H, Kumar A, Mohan A.

3 Biotech. 2014 Dec;4(6):579-589. doi: 10.1007/s13205-014-0194-0. Epub 2014 Jan 19.

5.

Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders.

Suryadevara U, Bruijnzeel DM, Nuthi M, Jagnarine DA, Tandon R, Bruijnzeel AW.

Curr Neuropharmacol. 2017;15(6):800-814. doi: 10.2174/1570159X14666161101095325.

6.

Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues.

Russo EB.

Front Pharmacol. 2016 Sep 14;7:309. doi: 10.3389/fphar.2016.00309. eCollection 2016. Review.

7.

Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation.

Burfeind KG, Yadav V, Marks DL.

Curr Neurol Neurosci Rep. 2016 Nov;16(11):98. Review.

8.

Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines.

Zgair A, Wong JC, Lee JB, Mistry J, Sivak O, Wasan KM, Hennig IM, Barrett DA, Constantinescu CS, Fischer PM, Gershkovich P.

Am J Transl Res. 2016 Aug 15;8(8):3448-59. eCollection 2016.

9.

Symptomatic Management of Multiple Sclerosis-Associated Tremor Among Participants in the NARCOMS Registry.

Meador W, Salter AR, Rinker JR 2nd.

Int J MS Care. 2016 May-Jun;18(3):147-53. doi: 10.7224/1537-2073.2015-008.

10.

Synthesis of (-)-Cannabimovone and Structural Reassignment of Anhydrocannabimovone through Gold(I)-Catalyzed Cycloisomerization.

Carreras J, Kirillova MS, Echavarren AM.

Angew Chem Int Ed Engl. 2016 Jun 13;55(25):7121-5. doi: 10.1002/anie.201601834. Epub 2016 Apr 27.

11.

Is the medical use of cannabis a therapeutic option for children?

Rieder MJ; Canadian Paediatric Society, Drug Therapy and Hazardous Substances Committee.

Paediatr Child Health. 2016 Jan-Feb;21(1):31-4.

12.

Marijuana Legalization: Impact on Physicians and Public Health.

Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC.

Annu Rev Med. 2016;67:453-66. doi: 10.1146/annurev-med-050214-013454. Epub 2015 Oct 19. Review.

13.

Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.

de Vries M, Van Rijckevorsel DC, Vissers KC, Wilder-Smith OH, Van Goor H.

Br J Clin Pharmacol. 2016 Mar;81(3):525-37. doi: 10.1111/bcp.12811. Epub 2016 Jan 17.

14.

U.S. Policy Responses to Calls for the Medical Use of Cannabis.

Hall W.

Yale J Biol Med. 2015 Sep 3;88(3):257-64. eCollection 2015 Sep. Review.

15.

Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.

Notcutt WG.

Neurotherapeutics. 2015 Oct;12(4):769-77. doi: 10.1007/s13311-015-0383-5. Review.

16.

Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?

Arjmand S, Vaziri Z, Behzadi M, Abbassian H, Stephens GJ, Shabani M.

Neurotherapeutics. 2015 Oct;12(4):778-87. doi: 10.1007/s13311-015-0367-5. Review.

17.

Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders.

Belendiuk KA, Baldini LL, Bonn-Miller MO.

Addict Sci Clin Pract. 2015 Apr 21;10:10. doi: 10.1186/s13722-015-0032-7. Review.

18.

Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells.

Jean-Gilles L, Braitch M, Latif ML, Aram J, Fahey AJ, Edwards LJ, Robins RA, Tanasescu R, Tighe PJ, Gran B, Showe LC, Alexander SP, Chapman V, Kendall DA, Constantinescu CS.

Acta Physiol (Oxf). 2015 May;214(1):63-74. doi: 10.1111/apha.12474. Epub 2015 Mar 10.

19.

The therapeutic potential of cannabinoids for movement disorders.

Kluger B, Triolo P, Jones W, Jankovic J.

Mov Disord. 2015 Mar;30(3):313-27. doi: 10.1002/mds.26142. Epub 2015 Feb 4. Review.

20.

Protective effects of cannabidiol on lesion-induced intervertebral disc degeneration.

Silveira JW, Issy AC, Castania VA, Salmon CE, Nogueira-Barbosa MH, GuimarĂ£es FS, Defino HL, Del Bel E.

PLoS One. 2014 Dec 17;9(12):e113161. doi: 10.1371/journal.pone.0113161. eCollection 2014.

Supplemental Content

Support Center